The Canadian real estate investor Oxford Properties Group has acquired a life science park in Cambridge, UK for £45 million as part of a strategy to service the global life science sector. The park, 310 Cambridge Science Park, is currently let to AstraZeneca Plc until November 2023, after which the company will move to new headquarters in the area.
